To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
-
Patent number: 9377466Abstract: A molecular tool for use in a method of providing a molecule that is capable of binding a target molecule based on a set of polypeptides. A polypeptide having a sequence selected from SEQ ID NOs 1-32. The polypeptide may be used in a method of screening for a ligand-polypeptide conjugate capable of binding a target molecule for the ligand. A ligand-polypeptide conjugate, useful e.g. in therapy.Type: GrantFiled: September 6, 2011Date of Patent: June 28, 2016Assignee: Modpro ABInventors: Lars Baltzer, Adam Slosarczyk, Jonas Bergquist, Anders Virtanen
-
Patent number: 9340820Abstract: Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use.Type: GrantFiled: August 26, 2010Date of Patent: May 17, 2016Assignee: Queen's University of BelfastInventors: Stella Lorraine Martin, Brian Walker
-
Patent number: 9303284Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP (SEQ ID NO: 9), and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP (SEQ ID NO: 10). In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.Type: GrantFiled: March 31, 2008Date of Patent: April 5, 2016Assignee: BioMadison, Inc.Inventors: Robert D. Fish, Min Dong
-
Patent number: 9284659Abstract: A method for crystallizing a substance dissolved in a solvent, including the following steps: introducing a solvent volume containing the substance into a chamber having a preset temperature, humidity, and gas composition, adding a predetermined volume of a precipitant to the solvent volume containing the substance, allowing the solvent to evaporate while simultaneously observing structural changes in the solvent volume containing the substance and the precipitant by means of dynamic light scattering, detecting weight changes and determining the molarities, making an association with the location in the phase diagram on the basis of the DLS measurement and the results of the molarity determination, allowing a predetermined number of crystal nuclei to form by adding solvent or adding precipitant, putting the solvent volume containing the substance and the precipitant into a metastable state by adding solvent and/or protein solution or by allowing the concentration of the dissolved substance to decrease by alloType: GrantFiled: June 30, 2011Date of Patent: March 15, 2016Assignee: Xtal Concepts GmbHInventors: Christian Betzel, Rolf Hilgenfeld, Dierk Hilterhaus, Thomas Klupsch, Peter Muehlig, Karsten Dierks, Arne Meyer
-
Patent number: 9261443Abstract: Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.Type: GrantFiled: May 8, 2013Date of Patent: February 16, 2016Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Patent number: 9249451Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a flexible peptide spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. The cleavage site sequence is a protease cleavage site, and the flexible spacer peptide is positioned and dimensioned to facilitate an electronic hop between the donor and acceptor label.Type: GrantFiled: February 25, 2015Date of Patent: February 2, 2016Assignee: BIOMADISON, INC.Inventors: Robert D. Fish, Min Dong
-
Patent number: 9201073Abstract: This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Usp14 (human), an endogenous inhibitor of the proteasome. The methods and compositions partially or completely reduce the inhibitory activity of Usp14 on a proteasome, thereby specifically enhancing the protein-degradation activity of the proteasome. The invention also provides methods of screening to identify inhibitors of Ubp6, Usp14, and/or both Ubp6 and Usp14.Type: GrantFiled: September 10, 2013Date of Patent: December 1, 2015Assignee: President and Fellows of Harvard CollegeInventors: Daniel J. Finley, John W. Hanna, Nathaniel A. Hathaway, Randall W. King, Byung-Hoon Lee
-
Patent number: 9193989Abstract: The present invention provides methods of identifying an agent that modulates PRPK, TPRKB, OSGEP, LAGE3 and its homologs, PRPK/TPRKB complex, and/or KEOPS complex. The present invention also provides compositions of such agents and methods of treating a disease, disorder, or condition associated with PRPK, TPRKB, OSGEP, LAGE3 and its homologs family (CT antigens), PRPK/TPRKB complex, and/or KEOPS complex using such an agent or composition.Type: GrantFiled: June 17, 2011Date of Patent: November 24, 2015Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Eun Sun Park, Henry E. Pelish, Astrid S. Clarke, Grace L. Williams, Maria Paola Castaldi, Alexander Arefolov, Jennifer E. Ring, Matthew D. Shair, Randall W. King
-
Patent number: 9182400Abstract: Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.Type: GrantFiled: December 21, 2007Date of Patent: November 10, 2015Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Patent number: 9175038Abstract: Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament.Type: GrantFiled: May 17, 2010Date of Patent: November 3, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Terrence R. Burke, Jr., Fa Liu, Kyung S. Lee, Jung-Eun Park
-
Patent number: 9116152Abstract: The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood.Type: GrantFiled: April 17, 2012Date of Patent: August 25, 2015Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Young Ki Paik, Keun Na
-
Patent number: 9116151Abstract: Disclosed is a method and associated device for the rapid identification of viable bacterial contaminants in food products. The method detects viable microbes by using a combined ATP-bioluminescence immunoassay. Escherichia coli O157:H7 and Salmonella enterica serovar Typhimurium were selected as target organisms in various matrices including ground beef homogenate, apple juice, milk, and phosphate-buffered saline. Specific antibodies were immobilized on the surface of well plates in which the sample matrices were incubated. The plates were washed, and the wells were incubated with BacTiter-Glo reagent in Mueller-Hinton II broth. Bioluminescent output was measured with a luminometer and signal-to-noise ratios were calculated. The LOD was not affected by the presence of non-target cells. A strong linear correlation was observed between the number of cells and luminescent output over 4 orders of magnitude.Type: GrantFiled: July 26, 2013Date of Patent: August 25, 2015Assignee: University of South FloridaInventors: Daniel V. Lim, Dawn M. Hunter
-
Patent number: 9079963Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.Type: GrantFiled: November 26, 2012Date of Patent: July 14, 2015Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Stefan Barth, Katharina Kolberg, Christiane Püttmann, Severin Schmies
-
Patent number: 9063089Abstract: Provided is an optical measuring apparatus including a light irradiating unit that irradiates a sample flowing through a flow path with light, a light detecting unit that detects optical information emitted from the sample due to light irradiation by the light irradiating unit, and a rate information adding unit that adds a predetermined display corresponding to a flow amount of the sample per unit time obtained from the optical information to a waveform data graph obtained from the optical information.Type: GrantFiled: August 29, 2012Date of Patent: June 23, 2015Assignee: SONY CORPORATIONInventor: Yosuke Muraki
-
Patent number: 9045794Abstract: The present invention features compositions and methods for the detection or measurement of oxalate in a sample. Such compositions include test devices that provide for the rapid and accurate detection of oxalate in a sample from a biological fluid. Advantageously, the compositions can be used to monitor the oxalate levels of a patient at a point of care (e.g., at the patient's home, clinic, physician's office, or other clinical setting).Type: GrantFiled: February 7, 2012Date of Patent: June 2, 2015Assignee: University of Florida Research Foundation, Inc.Inventors: Ammon B. Peck, Cuong Q. Nguyen, Nigel G. John Richards
-
Publication number: 20150148248Abstract: The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.Type: ApplicationFiled: May 23, 2013Publication date: May 28, 2015Inventors: Olivier Chinot, Emeline Tabouret
-
Publication number: 20150147309Abstract: The present invention relates to an allosteric non-inhibitory chaperone of the lysosomal acid alpha-glucosidase (GAA) for use in the treatment of a pathological condition characterized by a deficiency of the lysosomal acid alpha-glucosidase (GAA), to pharmaceutical composition thereof, to a method for increasing the activity of GAA in a subject and to a method for identifying an allosteric non-inhibitory chaperone for GAA.Type: ApplicationFiled: June 6, 2013Publication date: May 28, 2015Inventors: Giancarlo Parenti, Caterina Porto, Marco Moracci, Maria Carmina Ferrara, Beatrice Cobucci-Ponzano, Generoso Andria
-
Publication number: 20150148661Abstract: A system for measuring analyte concentrations has porous-walled nanocontainers containing multiple magnetic nanoparticles, the magnetic nanoparticles coated with a selective binder that is analyte-responsive and binds a the analyte, an indicator substance releasable from the selective binder by the analyte, or an indicator substance cleavable by the analyte, apparatus for exposing the nanocontainers to a fluid potentially containing the analyte, and magnetic spectroscopy of Brownian motion sensing apparatus for detecting agglutination of the nanoparticles or binding of analyte to the nanoparticles.Type: ApplicationFiled: June 14, 2013Publication date: May 28, 2015Applicant: The Trustees of Dartmouth CollegeInventors: John B. Weaver, Barjor Gimi, Karl Griswold
-
Publication number: 20150147762Abstract: Pancreatic cancer can be detected using a monoclonal antibody which binds to pancreatic RNase 1 when a site in pancreatic RNase 1 capable of being modified with an N-glycan chain is not linked to a glycan chain, but which does not bind to pancreatic RNase 1 when an N-glycan chain is linked to the site. Also provided is a monoclonal antibody which can bind to pancreatic RNase 1 simultaneously with the binding of the aforementioned antibody to pancreatic RNase 1, and determining the ratio of A to B using the antibodies, wherein A represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain, wherein an N-glycan chain is linked or not linked to the site; and B represents the amount of the site located in the pancreatic RNase 1 capable of being modified with an N-glycan chain.Type: ApplicationFiled: June 6, 2013Publication date: May 28, 2015Applicant: TOSOH CORPORATIONInventor: Daisuke Nakatani
-
Publication number: 20150148411Abstract: Provided are compositions and methods related to mutations in the Myh9 gene for aiding in diagnosing a subject as having an aggressive form of a cancer, for identifying an individual as a candidate for treatment with a nuclear export inhibitor, for determining whether tumor cells have defective p53 nuclear transportation, and for treating an individual diagnosed with an aggressive cancer.Type: ApplicationFiled: November 25, 2014Publication date: May 28, 2015Inventors: Daniel Schramek, Elaine Fuchs
-
Patent number: 9040249Abstract: Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates.Type: GrantFiled: October 31, 2012Date of Patent: May 26, 2015Assignees: Beckman Coulter, Inc., University Health NetworkInventors: David Hedley, Sue Chow, T. Vincent Shankey
-
Publication number: 20150139980Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.Type: ApplicationFiled: May 6, 2013Publication date: May 21, 2015Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
-
Publication number: 20150140573Abstract: The present invention relates to a method of detecting ?-(1?6)-glucosidase activity in a sample. The method is for example useful for determining the limit dextrinase activity in a sample. The method involves use of an oligosaccharide substrate of the formula X-(glucoside)n-*(glucoside)m-Z—Y, where X is a blocking group, -* is a ?-(1?6)-glucosidic linkage and Y is a detectable label. Upon cleavage of the ?-(1?6)-glucosidic linkage, the detectable label is released and thus the ?-(1?6)-glucosidase activity can be determined. The invention also relates to the oligosaccharide substrate per se.Type: ApplicationFiled: June 7, 2013Publication date: May 21, 2015Inventors: Marie Bøjstrup, Caspar Elo Christensen, Ole Hindsgaul
-
Publication number: 20150140127Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.Type: ApplicationFiled: June 25, 2013Publication date: May 21, 2015Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
-
Publication number: 20150141385Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.Type: ApplicationFiled: January 28, 2015Publication date: May 21, 2015Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
-
Publication number: 20150140124Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.Type: ApplicationFiled: November 10, 2014Publication date: May 21, 2015Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Publication number: 20150141273Abstract: The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer.Type: ApplicationFiled: April 26, 2013Publication date: May 21, 2015Inventors: Linda Janna Willemien Bosch, Meike De Wit, Beatriz Pinto Morais de Carvalho, Remond Johnnes Adriaan Fijneman, Gerrit Albert Meijer, Comelia Ramona Jimenez, Sander Rogier Piersma, Viet Thang Pham, Gideon Oudgenoeg
-
Publication number: 20150141489Abstract: A method of determining a treatment for an inflammatory disorder in a subject, is disclosed. The method comprises determining an amount of SRSF6 in a sample from the subject, wherein an amount of the SRSF6 is indicative of the treatment. Methods of diagnosing inflammatory disorders and treating same are also disclosed.Type: ApplicationFiled: May 16, 2013Publication date: May 21, 2015Inventors: Rotem Karni, Vered Ben Hur, Avraham Maimon
-
Patent number: 9034887Abstract: A method of identifying an antifungal agent which targets a DHODH protein (alias PyrE, dihydroorotate dehydrogenase, EC: 1.3.99.11) of a fungus comprising contacting a candidate substance with a fungal DHODH protein and determining whether the candidate substance binds or modulates the DHODH protein, wherein binding or modulation indicates that the candidate substance is an antifungal agent. Specific examples concern Aspergillus fumigatus and Candida albicans DHODH proteins. DHODH inhibitors with a Quinazolinone core are also disclosed.Type: GrantFiled: May 1, 2009Date of Patent: May 19, 2015Assignee: F2G LimitedInventors: Jason David Oliver, John Leslie Thain, Michael John Bromley, Graham Edward Morris Sibley, Michael Birch
-
Patent number: 9034321Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: May 3, 2011Date of Patent: May 19, 2015Assignees: aTyr Pharma, Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
-
Publication number: 20150132771Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), —combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.Type: ApplicationFiled: December 17, 2014Publication date: May 14, 2015Inventors: Ziad Mallat, Sotirios Tsimikas
-
Publication number: 20150133336Abstract: The present invention concerns a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of a) exposing the non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to the ligand; and b) analysing said sample for the presence of soluble or native target protein using two or more affinity reagents capable of binding to said soluble or native target protein with a higher affinity than to an unfolded and/or insoluble form of said target protein. The invention particularly concerns the use of two affinity reagents (e.g. antibodies) which are capable of distinguishing between soluble or native, and unfolded and/or insoluble forms of a target protein and whose detection e.g. by FRET based technology, allows the performance of the method without a separation step.Type: ApplicationFiled: January 16, 2015Publication date: May 14, 2015Inventors: Pär NORDLUND, Daniel Martinez MOLINA, Thomas LUNDBÄCK
-
Publication number: 20150133524Abstract: The invention provides therapeutic and prophylactic compounds and methods for altering the activity of pyruvate dehydrogenase kinase (e.g. PDK1, PDK2, PDK3, PDK4). Such therapies are useful for the treatment of neoplasia. The invention further provides therapeutic and prophylactic compounds and methods of altering pyruvate dehydrogenase activity to treat or prevent cell death related to ischemia.Type: ApplicationFiled: October 15, 2014Publication date: May 14, 2015Inventors: Chi V. Dang, Jung-whan Kim, Gregg L. Semenza
-
Publication number: 20150132772Abstract: Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.Type: ApplicationFiled: January 8, 2015Publication date: May 14, 2015Inventors: Lars Otto Uttenthal, Margarita Ghiglione Juanes, Kristian Bangert
-
Publication number: 20150132770Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: ApplicationFiled: August 22, 2014Publication date: May 14, 2015Inventors: Claus Oxvig, Michael Toft Overgaard
-
Publication number: 20150132769Abstract: Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mito-chondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin.Type: ApplicationFiled: March 1, 2013Publication date: May 14, 2015Inventors: R. Mark Payne, Gregory R. Wagner, Clifford M. Babbey, P. Melanie Pride
-
Publication number: 20150125466Abstract: The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (“MMP-23”) by the tumor cell or the peripheral blood cell; comprising the measured expression level of MMP-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher MMP-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy. The present invention also relates to methods for increasing production of tumor infiltrating leucocytes (“TILs”) in a subject, methods of identifying a subject as a candidate for adoptive T-cell therapy using T-cells that primarily express KCa3.Type: ApplicationFiled: May 1, 2013Publication date: May 7, 2015Inventors: Michelle Krogsgaard, Iman Osman
-
Publication number: 20150126622Abstract: Necrotizing Enterocolitis (NEC) biomarkers, NEC biomarker panels, and methods for obtaining a NEC signature for a sample are provided. Also provided are methods, compositions, and kits for making a Necrotizing Enterocolitis (NEC) assessment of an individual, e.g. for diagnosing NEC in a patient, prognosing NEC in a patient, treating an NEC patient, etc. These methods find use in a number of applications, such as diagnosing and treating infants who are suspected of having NEC, intestinal perforation (IP), or sepsis.Type: ApplicationFiled: June 10, 2013Publication date: May 7, 2015Inventors: Karl G. Sylvester, Guozhong Tao
-
Publication number: 20150125452Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.Type: ApplicationFiled: November 6, 2014Publication date: May 7, 2015Inventors: Timothy R. Wilson, Hartmut Koeppen, Mark Merchant, Jeffrey Settleman
-
Publication number: 20150125876Abstract: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27.Type: ApplicationFiled: December 24, 2014Publication date: May 7, 2015Applicant: MCBI INC.Inventors: Kazuhiko UCHIDA, Kohji MENO, Hideaki SUZUKI
-
Publication number: 20150126384Abstract: The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques.Type: ApplicationFiled: November 6, 2013Publication date: May 7, 2015Applicant: VERMILLION, INC.Inventors: Estrid Hogdall, Eric T. Fung, Jarle IB Christensen, Claus Hogdall
-
Publication number: 20150126580Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.Type: ApplicationFiled: December 19, 2012Publication date: May 7, 2015Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
-
Publication number: 20150119281Abstract: A phosphine derivative of DyLight dyes modified with ethylene glycol or (poly)ethylene glycol groups. In one embodiment, the compounds are useful in chemoselective ligation reactions.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Applicants: Pierce Biotechnology, Inc., Dyomics GmbHInventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Suk J. Hong, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann
-
Publication number: 20150118675Abstract: The present invention provides an immunochromatography detection method capable of suppressing non-specific reactions. The present invention relates to an immunochromatography detection method including: a step of adding an analyte dilution solution containing an analyte to a chromatography medium; a step of recognizing a detection target by a labeling substance modified with gold nanoparticles, which is dry-retained at a labeling substance retaining part; a step of developing a composite of the labeling substance and the detection target as a mobile phase; and a step of detecting the detection target in the developed mobile phase at a judgment part, wherein the labeling substance is protected with a polyalkylene glycol having one or more mercapto groups and/or a derivative thereof and then dry-retained together with arginine and casein at the labeling substance retaining part.Type: ApplicationFiled: March 13, 2013Publication date: April 30, 2015Inventor: Daisuke Ito
-
Publication number: 20150119410Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.Type: ApplicationFiled: October 26, 2012Publication date: April 30, 2015Applicants: Millennium Pharmaceuticals, Inc, Massachusetts General HospitalInventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
-
Publication number: 20150118690Abstract: A sample analyzer has an illuminator for illuminating an assay sample to cause luminescence, and a support for a sample vessel containing the assay sample. The support is adapted to position the assay sample proximate the illuminator. A detector is positioned along an optical axis extending from the illuminator, through the positioned assay sample, to the detector, so as to detect the luminescence from the assay sample. A reflector is removably disposed between the illuminator and the assay sample so as to reflect a portion of the luminescence back through the positioned assay sample toward the detector.Type: ApplicationFiled: April 23, 2013Publication date: April 30, 2015Applicant: Siemens Healthcare Diagnostic Inc.Inventors: Jeffrey R. Jasperse, Normand P. Desmarais
-
Publication number: 20150119282Abstract: Markers are provided for genetic and epigenetic diagnosis of embryos to determine those of which are more likely to be chromosomally normal and advance in development.Type: ApplicationFiled: October 30, 2014Publication date: April 30, 2015Inventors: Shawn L. Chavez, Renee A. Reijo Pera, Sohyun L. McElroy, Barry Behr, Lynn M. Westphal
-
Publication number: 20150119475Abstract: The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.Type: ApplicationFiled: May 2, 2013Publication date: April 30, 2015Inventors: Jim Lorens, Crina Tiron
-
Publication number: 20150119263Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.Type: ApplicationFiled: August 30, 2012Publication date: April 30, 2015Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, FOX CHASE CANCER CENTERInventors: Alan T. Johnson, JR., Mitchell Lerner, Matthew K. Robinson, Tatiana Pazina, Dustin Brisson, Jennifer Dailey
-
Publication number: 20150118699Abstract: Markers useful in diagnosing disseminated intravascular coagulation (DIC) or infectious DIC are provided. In a method for detecting DIC of the present invention, sCD14-ST in a sample is measured. In a method of detecting infectious DIC of the present invention, sCD14-ST and a coagulation-related marker in a sample are measured.Type: ApplicationFiled: April 26, 2013Publication date: April 30, 2015Inventor: Hiroyasu Ishikura